 Seres has seen 863 upside YTD on the back of positive top-line data in their phase 3 SER-109 study, which helps prove their microbiome hypotheses. Management have strengthened the cash position and the balance sheet, with key collaborations with Nestle and via equity capital, thus runaway is now over 2 years. 